Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
802.9 INR | +9.95% | +17.83% | +18.82% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- With an expected P/E ratio at 69.9 and 54.43 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is not the most generous with respect to shareholders' compensation.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+18.82% | 985M | B- | ||
-16.58% | 8.49B | B+ | ||
+58.90% | 4.08B | C+ | ||
-39.78% | 2.42B | B- | ||
-10.33% | 2.42B | - | ||
-8.91% | 2.33B | B- | ||
-2.53% | 2.01B | C- | ||
-19.90% | 1.53B | A- | ||
-38.30% | 1.26B | C+ | ||
+2.19% | 1.07B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- VIJAYA Stock
- Ratings Vijaya Diagnostic Centre Limited